Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$12.42 USD
+0.60 (5.08%)
Updated May 30, 2024 04:00 PM ET
After-Market: $12.38 -0.04 (-0.32%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Cidara Therapeutics, Inc. [CDTX]
Reports for Purchase
Showing records 41 - 60 ( 145 total )
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With Positive ReSTORE Data, Rezafungin Regulatory Filings Expected to Begin in Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Would Be Buyers Ahead of Pivotal Data Readout This Month; Assume Buy, $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Ph 3 Topline Data Reiterated for YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Recent Deal Extends Cash Runway Past Key Inflection Points
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; ReSTORE Still on Track for YE:2021 Readout
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Ph 3 ReSTORE Data Expected by YE:2021
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ReSPECT the Progress with First Ph 3 Patient Enrolled
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R